CN104435487A - Traditional Chinese medicine for treating hypertension complicated with diabetic fundi disease and preparation method thereof - Google Patents

Traditional Chinese medicine for treating hypertension complicated with diabetic fundi disease and preparation method thereof Download PDF

Info

Publication number
CN104435487A
CN104435487A CN201410743295.1A CN201410743295A CN104435487A CN 104435487 A CN104435487 A CN 104435487A CN 201410743295 A CN201410743295 A CN 201410743295A CN 104435487 A CN104435487 A CN 104435487A
Authority
CN
China
Prior art keywords
parts
chinese medicine
traditional chinese
diabetic
radix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410743295.1A
Other languages
Chinese (zh)
Inventor
周连才
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201410743295.1A priority Critical patent/CN104435487A/en
Publication of CN104435487A publication Critical patent/CN104435487A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/287—Chrysanthemum, e.g. daisy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/288—Taraxacum (dandelion)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
    • A61K36/296—Epimedium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/482—Cassia, e.g. golden shower tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/488—Pueraria (kudzu)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/746—Morinda
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815—Lycium (desert-thorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A61K36/8888—Pinellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Abstract

The invention belongs to the field of traditional Chinese medicines and relates to a traditional Chinese medicine for treating hypertension complicated with diabetic fundi disease and a preparation method thereof. Aiming at the defect in the prior art that chemotherapeutic medicine for treating hypertension complicated with diabetic fundi disease is relatively great in hepatotoxicity while traditional Chinese medicine therapeutics are not excellent in curative effect generally, the invention provides a traditional Chinese medicine for treating or preventing hypertension complicated with diabetic fundi disease. The traditional Chinese medicine comprises the following components in parts by weight: 20 parts of scutellaria baicalensis, 11 parts of eucommia ulmoides, 8 parts of wolfberries, 10 parts of salviae miltiorrhizae, 10 parts of morinda officinalis, 6 parts of epimedium koreanum, 12 parts of semen cassia, 10 parts of plantain herb, 16 parts of roots of kudzu vines, 12 parts of dandelion, 10 parts of pinellia ternate, 15 parts of mother chrysanthemum, 5 parts of folium artemisiae argyi and 10 parts of liquorice. The traditional Chinese medicine composition has a good curative effect in treating or preventing hypertension complicated with diabetic fundi disease, is low in toxic or side effect and has a remarkable clinical promotional value.

Description

A kind ofly treat Chinese medicine of hypertension complicated with diabetes mellitus retinopathy and preparation method thereof
Technical field
The invention belongs to field of medicaments, be specifically related to a kind ofly treat Chinese medicine composition of hypertension complicated with diabetes mellitus retinopathy and preparation method thereof.
Background technology
Diabetic fundus disease is the consequence of diabetic microangiopathy, and because diabetes cause retinal capillary wall to damage, blood is hypercoagulability in addition, easily causes thrombosis and blood stasis, even angiorrhexis.At present, the retinopathy that diabetes cause causes VI and blind main cause.This disease morbidity early stage patient is without any sensation, if make regular check on optical fundus, doctor can see whether your optical fundus changes, and is at this moment the best opportunity of prevention.Mid-term there will be retinal edema, and eye may occur new vessels and hemorrhage to vitreous chamber.Now can feel blurred vision, have shadow to wave at the moment, metamorphopsia etc.During late period, vitreous hemorrhage is serious, retina shedding, even blind.Along with the raising that medical personnel is familiar with diabetic fundus disease, find hypertension for diabetic fundus disease development and be related very close.Hypertensive patient raises due to blood pressure long duration, can cause more amphiblestroid pathological changes.Early stage retinal arterioles spasm, checks that visible small artery attenuates, reflective enhancing.If continue spasm, can develop into arteriosclerosis, arteriovenous infall has impression phenomenon, and copper wire shape or filamentary silver shape tremulous pulse can appear in severe patient.If PD, blood pressure sharply increases, and can occur retinal edema, hemorrhage and ooze out, further developing increased intracranial pressure can merge papilloedema.Therefore, diabetic fundus disease patient will note paying close attention to hypertensive treatment, researches and develops one and treats the effective medicine of hypertension complicated with diabetes mellitus retinopathy and then become and be badly in need of in the industry.
Mainly there are laser therapy and Drug therapy two kinds of modes in the retinopathy caused for diabetes clinically at present. and wherein retinal laser therapy is the basic means for the treatment of hypertension complicated with diabetes mellitus retinopathy, directly can solidify closed new vessels, microangioma and have the blood capillary of fluorescence leakage, laser therapy makes part retinal tissue by laser photocoagulation, remaining retina can obtain abundanter blood oxygen supply, blocking-up new vessels produces, thus stops the development of retinopathy.But this treatment means only can play retarding action for diabetic retinopathy, the treatment situation for conditions of patients is poor, and medical expense is high, and patient is difficult to bear.The incidence rate that Drug therapy effectively can reduce diabetic ocular fundus diseases is carried out for diabetics, and Drug therapy also can play direct therapeutical effect to diabetic retinopathy usually.Western medicine effectively cannot treat diabetic ophthalmopathy, and long-term taking Western medicine has more side effect, Chinese medicine curative effect in treatment is better, the symptom such as vitreous hemorrhage, macular edema caused for diabetes when having had at present the treatment of multiple Chinese medicine preparation such as peace snow granule, sugared net soup, discharge opeing soup for diabetic retinopathy has must mitigation, but still it is not satisfied to there is therapeutic effect, the defect that relapse rate is high.Therefore, still there is very large demand for effective medicine of diabetic ophthalmopathy in medical care patient.The present invention, namely from pathogeny and the clinical symptoms of diabetic ophthalmopathy, provides that a kind of particularly diabetic retinopathy can treating both the principal and secondary aspects of a disease to hypertension complicated with diabetes mellitus retinopathy, the medicine that relapse rate is low.
Summary of the invention
For the deficiency of current hypertension complicated with diabetes mellitus retinopathy clinical treatment medicine, first object of the present invention is to provide a kind of Chinese medicine composition for the treatment of hypertension complicated with diabetes mellitus retinopathy, this Chinese medicine composition has when treating hypertension complicated with diabetes mellitus retinopathy the treatment advantage that therapeutic effect is remarkable, side effect is little, permanence operation is good, has fine medical application prospect.Chinese medicine composition of the present invention, according to components by weight percent meter, it primarily of following weight portion raw material obtain: Radix Scutellariae 20 parts, the Cortex Eucommiae 11 parts, Fructus Lycii 8 parts, Radix Salviae Miltiorrhizae 10 parts, Radix Morindae Officinalis 10 parts, towards Herba Epimedii 6 parts, Semen Cassiae 12 parts, Herba Plantaginis 10 parts, Radix Puerariae 16 parts, Herba Taraxaci 12 parts, the Rhizoma Pinelliae 10 parts, Flos Chrysanthemi Indici 15 parts, Folium Artemisiae Argyi 5 parts, 10 parts, Radix Glycyrrhizae.
In Chinese medicine composition described above, various Chinese medicinal components is all got its conventional agents area and is used as medicine.The mutual compatible combination of said medicine in the present invention, complements one another, and reaches the object of blood sugar lowering, antiinflammatory, liver heat removing and eyesight improving, has good curative effect to hypertension complicated with diabetes mellitus retinopathy.
Fructus Lycii 6 parts, Herba Ecliptae 12 parts, the Radix Paeoniae Alba 8 parts can also be contained in the present invention's Chinese medicine composition described above.Fructus Lycii, Herba Ecliptae, the Radix Paeoniae Alba three kinds of medicines are used in conjunction, and not only significantly can improve the microangiopathies situation of patient, and three kinds of medicines and aforementioned pharmaceutical compositions coupling of the present invention can strengthen its therapeutic effect to hypertension complicated with diabetes mellitus retinopathy further.
The method preparing Chinese medicine composition of the present invention is as follows: each medical material getting above-mentioned components by weight percent, adds the 5-15 water doubly of medical material gross weight, soaks 10-60 minute, decoct 1-4 time, each 1-3 hour, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.05-1.25, and this relative density is testing result at 60 c, and adding ethanol to alcohol content is 60-90% (v/v), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, to obtain final product.The above-mentioned Chinese medicine composition of the present invention can be prepared into pharmaceutical preparation conventional clinically further, is preferably mixture, tablet, capsule.
The present invention also discloses a kind of purposes of above-mentioned Chinese medicine composition, i.e. the purposes of above-mentioned Chinese medicine composition in preparation treatment or prophylaxis of hypertension complication with diabetes retinopathy medicine.By pharmacodynamic experiment, the present invention confirms that Chinese medicine composition causes rat diabetes retinopathy for streptozotocin and has good therapeutic effect.Compare with model group, Chinese medicine composition high and low dose group and positive group all can reduce EB value (P<0.05), obvious reduction E/P (P<0.01), and can retinal morphology be recovered, Chinese medicine composition high and low dose group also obviously can reduce retinal tissue MDA value, raise its SOD value (P<0.01), and positive group little on the impact of SOD and MDA.
In a word, the present invention compared with prior art, have the activity for the treatment of hypertension complicated with diabetes mellitus retinopathy very well, and the present invention is pure Chinese medicinal preparation, to human body particularly to liver avirulence.When the present invention uses as hypertension complicated with diabetes mellitus retinopathy medicine, drug effect is comprehensive, while blood sugar lowering antiinflammatory, liver heat removing and eyesight improving, effect of activating blood circulation to dissipate blood stasis, dispelling phlegm and eliminating dampness can also be obtained, the mutual compatible combination of ladies and gentlemen's medicine, complements one another, and plays synergism, the object strengthening immunologic function can be reached, and Chinese medicine composition preparation of the present invention is simple, and substantially nontoxic, raw material is easy to get, be suitable for popular use, there is good application prospect.
Detailed description of the invention
Further describe the present invention below by way of detailed description of the invention, but the present invention is not limited only to following examples.Within the scope of the invention or not departing from content of the present invention, spirit and scope, Chinese medicine composition of the present invention is suitably improved, replaces the identical component of effect, will become apparent to those skilled in the art that they are all deemed to be included within scope of the present invention.
Part I, the preparation of Chinese medicine composition of the present invention
Embodiment 1 Chinese medicine composition mixture of the present invention
Prescription: Radix Scutellariae 20 parts, the Cortex Eucommiae 11 parts, Fructus Lycii 8 parts, Radix Salviae Miltiorrhizae 10 parts, Radix Morindae Officinalis 10 parts, towards Herba Epimedii 6 parts, Semen Cassiae 12 parts, Herba Plantaginis 10 parts, Radix Puerariae 16 parts, Herba Taraxaci 12 parts, the Rhizoma Pinelliae 10 parts, Flos Chrysanthemi Indici 15 parts, Folium Artemisiae Argyi 5 parts, 10 parts, Radix Glycyrrhizae.
Preparation method: each medical material getting above-mentioned components by weight percent, adds the water of 5 times of medical material gross weight, soaks 30 minutes, decoct 2 times, each 2 hours, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.1, and this relative density is testing result at 60 c, adding ethanol to alcohol content is 75% (v/v), leaves standstill 24 hours, gets supernatant, recovery ethanol concentrates, and adds water to 1000ml, stirs evenly, subpackage, flowing steam sterilization 35min, obtains mixture.
Embodiment 2 Chinese medicine composition mixture of the present invention
Prescription: Radix Scutellariae 20 parts, the Cortex Eucommiae 11 parts, Fructus Lycii 8 parts, Radix Salviae Miltiorrhizae 10 parts, Radix Morindae Officinalis 10 parts, towards Herba Epimedii 6 parts, Semen Cassiae 12 parts, Herba Plantaginis 10 parts, Radix Puerariae 16 parts, Herba Taraxaci 12 parts, the Rhizoma Pinelliae 10 parts, Flos Chrysanthemi Indici 15 parts, Folium Artemisiae Argyi 5 parts, Radix Glycyrrhizae 10 parts of Fructus Lycii 6 parts, Herba Ecliptae 12 portions of Radix Paeoniae Albas 8 parts.
Preparation method: each medical material getting above-mentioned components by weight percent, adds the water of 5 times of medical material gross weight, soaks 30 minutes, decoct 2 times, each 2 hours, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.1, and this relative density is testing result at 60 c, adding ethanol to alcohol content is 75% (v/v), leaves standstill 24 hours, gets supernatant, recovery ethanol concentrates, and adds water to 1000ml, stirs evenly, subpackage, flowing steam sterilization 35min, obtains mixture.
Embodiment 3 Chinese medicine composition tablet of the present invention
Prescription: Radix Scutellariae 20 parts, the Cortex Eucommiae 11 parts, Fructus Lycii 8 parts, Radix Salviae Miltiorrhizae 10 parts, Radix Morindae Officinalis 10 parts, towards Herba Epimedii 6 parts, Semen Cassiae 12 parts, Herba Plantaginis 10 parts, Radix Puerariae 16 parts, Herba Taraxaci 12 parts, the Rhizoma Pinelliae 10 parts, Flos Chrysanthemi Indici 15 parts, Folium Artemisiae Argyi 5 parts, 10 parts, Radix Glycyrrhizae.
Preparation method: each medical material getting above-mentioned components by weight percent, adds the water of 10 times of medical material gross weight, soaks 60 minutes, decoct 1 time, each 1 hour, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.25, and this relative density is testing result at 60 c, adding ethanol to alcohol content is 80% (v/v), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, vacuum drying, granulation, tabletting and get final product.
Embodiment 4 Chinese medicine composition tablet of the present invention
Prescription: Radix Scutellariae 20 parts, the Cortex Eucommiae 11 parts, Fructus Lycii 8 parts, Radix Salviae Miltiorrhizae 10 parts, Radix Morindae Officinalis 10 parts, towards Herba Epimedii 6 parts, Semen Cassiae 12 parts, Herba Plantaginis 10 parts, Radix Puerariae 16 parts, Herba Taraxaci 12 parts, the Rhizoma Pinelliae 10 parts, Flos Chrysanthemi Indici 15 parts, Folium Artemisiae Argyi 5 parts, Radix Glycyrrhizae 10 parts of Fructus Lycii 6 parts, Herba Ecliptae 12 portions of Radix Paeoniae Albas 8 parts.
Preparation method: each medical material getting above-mentioned components by weight percent, adds the water of 10 times of medical material gross weight, soaks 60 minutes, decoct 1 time, each 1 hour, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.25, and this relative density is testing result at 60 c, adding ethanol to alcohol content is 80% (v/v), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, vacuum drying, granulation, tabletting and get final product.
Embodiment 5 Chinese medicinal composition capsules agent of the present invention
Prescription: Radix Scutellariae 20 parts, the Cortex Eucommiae 11 parts, Fructus Lycii 8 parts, Radix Salviae Miltiorrhizae 10 parts, Radix Morindae Officinalis 10 parts, towards Herba Epimedii 6 parts, Semen Cassiae 12 parts, Herba Plantaginis 10 parts, Radix Puerariae 16 parts, Herba Taraxaci 12 parts, the Rhizoma Pinelliae 10 parts, Flos Chrysanthemi Indici 15 parts, Folium Artemisiae Argyi 5 parts, 10 parts, Radix Glycyrrhizae.
Preparation method: each medical material getting above-mentioned components by weight percent, adds the water of 8 times of medical material gross weight, soaks 45 minutes, decoct 4 times, each 1.5 hours, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.2, and this relative density is testing result at 60 c, adding ethanol to alcohol content is 90% (v/v), leaves standstill 24 hours, gets supernatant, reclaim ethanol to concentrated, vacuum drying, granulates, encapsulated and get final product.
Embodiment 6 Chinese medicinal composition capsules agent of the present invention
Prescription: Radix Scutellariae 20 parts, the Cortex Eucommiae 11 parts, Fructus Lycii 8 parts, Radix Salviae Miltiorrhizae 10 parts, Radix Morindae Officinalis 10 parts, towards Herba Epimedii 6 parts, Semen Cassiae 12 parts, Herba Plantaginis 10 parts, Radix Puerariae 16 parts, Herba Taraxaci 12 parts, the Rhizoma Pinelliae 10 parts, Flos Chrysanthemi Indici 15 parts, Folium Artemisiae Argyi 5 parts, Radix Glycyrrhizae 10 parts of Fructus Lycii 6 parts, Herba Ecliptae 12 portions of Radix Paeoniae Albas 8 parts.
Preparation method: each medical material getting above-mentioned components by weight percent, adds the water of 8 times of medical material gross weight, soaks 45 minutes, decoct 4 times, each 1.5 hours, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.2, and this relative density is testing result at 60 c, adding ethanol to alcohol content is 90% (v/v), leaves standstill 24 hours, gets supernatant, reclaim ethanol to concentrated, vacuum drying, granulates, encapsulated and get final product.
Part II, the pharmacodynamics of Chinese medicine composition of the present invention is investigated
Embodiment 7 Chinese medicine composition composition oral preparation causes the effect of rat diabetes retinopathy to streptozotocin
1 animal grouping and modeling
SD rat 150, after adaptability raises one week, wherein normally feeds for 10 as a control group, after all the other Rat Fast 12h, prepares diabetes model by 50mg/kg left lower quadrant intracavitary administration 2% streptozotocin (STZ) solution.Streptozotocin solution is in configuring with 0.1mmol/L, pH4.5 citrate buffer solution before use.Matched group injects isodose citric acid, sodium citrate buffer solution.Detect the non-fasting glucose of rat tail vein after injection 72h, blood glucose value >=16.7mmol/L is defined as diabetes rat.Grouping and administration: modeling starts to calculate the course of disease after one week and starts administration.Get into mould rat 100 and be only divided into 5 groups at random by body weight, blood sugar level: Chinese medicine composition object height, in and low dose group, model group (normal saline), positive group.Each group all by dosage gastric infusion in table 1, every day 1 time, successive administration 4 weeks.Survey rat body weight weekly, to determine dosage.
2 testing indexs and assay method
2.1 Evans blue tracer quantitative assay retinal blood vessels leak amounts
Often group gets 6 rats, after anesthesia, EB liquid is slowly injected through tail vein by 45mg/kg dosage, can be observed large rathole and whole skin and become blue instantaneously, circulate after 120 minutes, open thoracic cavity and expose heart, mosquito forceps clamping postcava, by the capable left ventricle perfusion of ventricles liquid being preheated to 37 DEG C, cut off right auricle simultaneously, perfusion pressure 120mmHg (about 164cmH20), perfusion continues 3 minutes, to remove endovascular EB.After perfusion terminates, take out eyeball immediately, careful separation goes out retina, spends the night to dry and weighs.Retina and 150 μ L Methanamides are hatched 18 hours at 70 DEG C, then extract are moved in centrifuge tube, centrifuge at 4 DEG C, centrifugal 90min under 6000rpm/min.Get supernatant 100 μ L microplate reader and survey its absorbance (A) value, measure the absorption photometric value under 620nm and 740nm two kinds of wavelength respectively, get two value differences and the clean absorption photometric value final absorbance as sample.Each sample measures 3 times, and 5 seconds, interval, finally gets its meansigma methods, then tries to achieve EB concentration in sample according to EB standard solution absorbance difference in Methanamide.With retina dry weight (mg) standardization EB (ng) content, result is expressed as: ng/mg.
2.2 Biochemical Indexes and retinal morphology are observed
2.2.1 sample collection
After last administration, each group Rat Fast water 12h, measures blood glucose value, then etherization, vacuum test tube Culling heart blood, separation of serum; Extract rat eye, left eye is placed in 10% formalin solution and is fixed for retinal microvasculopathy reason and morphological observation, and right eye is blunt separation retina under condition of ice bath immediately, for detecting SOD activity, MDA content.
2.2.2 retinal tissue section and observation
Immunohistochemistry is observed: the formaldehyde eyeball taken off being placed in 10% is fixed on fixes 48h, removing anterior ocular segment is that eyecup is cut into three pieces by Fructus Citri tangerinae lobe sample, isolate retina, running water 24h, put into 3% trypsin solution of the Tris-HCl buffer solution with 0.1ml/L, pH7.8,37 DEG C of water bath with thermostatic control 80min, when after retinal tissue protein dissolution, retina is moved in water, vibrate gently, until the retinal blood pipe network of remaining layer of transparent, move on microscope slide, natural drying, PAS adds brazilwood extract dyeing.The retinal capillary morphological change of observation by light microscope rat, adopt computerized image analysis sgstem quantitative analysis, to the blood capillary of every routine retina digestion specimen, count the endotheliocyte in 5 visuals field and pericyte, calculate the ratio (E/P) of endotheliocyte and pericyte.
3 statistical analysis
Experimental data represents with mean ± S.D., and adopt SPSS software, statistical test independent samples t-test and single factor test F check, test level α=0.05.
4, result of the test and analysis
Chinese medicine composition composition oral preparation on the impact of rat diabetes retinopathy, macular edema in table 1, table 2.To make in retinal tissue after rat modeling success that SOD vigor reduces, MDA content and E/P raise and there is the rising of EB value, there is the phenomenons such as edema is hemorrhage in retina, model group has significant difference compared with normal group.Compare with model group, Chinese medicine composition high and low dose group and positive group all can reduce EB value (P<0.05), obvious reduction E/P (P<0.01), and can retinal morphology be recovered, Chinese medicine composition high and low dose group also obviously can reduce retinal tissue MDA value, raise its SOD value (P<0.01), and positive group little on the impact of SOD and MDA.
Table 1 Chinese medicine composition composition oral preparation is on the impact of rat diabetes retinopathy
Group Dosage EB value
Normal group Gavage equal-volume normal saline 12.27±0.53
Model group Gavage equal-volume normal saline 38.34±1.29
Positive controls Gavage gives the Calcium Dobesilate of 150mg/kg/d 24.16±0.95 *
Low group of Chinese medicine composition Gavage gives the Chinese medicine composition of 7mg/kg/d 21.39±0.86 *#
Chinese medicine composition object height group Gavage gives the Chinese medicine composition of 70mg/kg/d 19.83±0.76 **#
Compare with model group, *p < 0.05, *p < 0.01; Compared with positive controls, #p < 0.05; ##p < 0.01
Compared with breviscapine group, P < 0.05, P < 0.01;
Table 2 Chinese medicine composition composition oral preparation is on the impact of diabetic fundus disease rat SOD, MDA and E/P
Group SOD(U.mg -1) MDA(nmol.mg -1) E/P
Normal group 9.86±0.89 3.98±0.63 2.61±0.32
Model group 4.96±0.76 6.04±0.71 5.72±0.56
Positive controls 6.21±0.91 * 5.49±0.58 * 4.61±0.50 *
Low group of Chinese medicine composition 6.35±0.76 * 5.32±0.62 * 4.35±0.42 *
Chinese medicine composition object height group 6.78±0.68 *# 5.03±0.48 *# 4.18±0.35 *#
Compare with model group, *p < 0.05, *p < 0.01; Compared with positive controls, #p < 0.05; ##p < 0.01
Embodiment 8 Chinese medicine composition of the present invention is to the therapeutic effect of spontaneous hypertensive rat blood pressure
Spontaneous hypertensive rat 50, male, body weight (300 ± 20) g, purchased from The 2nd Army Medical College new drug An Ping center, after adaptability raises one week, is divided into 5 groups at random, often organizes 10.
Model control group: gavage gives same volume normal saline;
Positive controls: gavage gives Baicalin (Jiuzhitang Jinding Pharmaceutical Co., Ltd., Chengdu's production), crude drug amount 5mg/kg;
Low group of Chinese medicine composition: gavage gives Chinese medicine composition described in the embodiment of the present invention 1, crude drug amount 0.5g/kg;
Group in Chinese medicine composition: gavage gives Chinese medicine composition described in the embodiment of the present invention 1, crude drug amount 2g/kg;
Chinese medicine composition object height group: gavage gives Chinese medicine composition described in the embodiment of the present invention 1, crude drug amount 5g/kg;
Each group is gastric infusion, once a day, and totally 10 weeks.In experimentation, observe animal diet followed, survival condition and behavioral activity every day, every day measures body weight, according to body weight adjustment drug dose.Temperature of feeding controls at 18 DEG C-22 DEG C, humidity 45%-65%, Indoor Natural light.Upon administration first week, the 3rd week and the 6th week difference Measure blood pressure, with tail arterial blood pressure under BP-2006A intelligence non-invasive blood pressure measuring (Beijing Ruan Long company limited provides) measurement rat waking state.All measure 5 times between 2 hours to 5 hours after gastric infusion during measuring blood pressure, get the blood pressure of its average as this sample.
Table 3 hypertension compound recipe on the impact of spontaneous hypertensive rat blood pressure ( n=10) (mmHg)
●p < 0.05 is compared with model group, ● ●p < 0.01 is compared with model group; ▼positive controls compares p < 0.05.
From above result, Chinese medicine composition of the present invention and positive controls blood pressure drops amplitude compared with model group has significant difference, wherein the antihypertensive effect of Chinese medicine composition object height group of the present invention is the most excellent, and the Amplitude of Hypotensive after group, Chinese medicine composition object height group treat 6 weeks in low group of Chinese medicine composition, Chinese medicine composition and positive control medicine have the difference of significance.In visible Chinese medicine composition of the present invention, each component has obvious synergism in blood pressure lowering.

Claims (5)

1. a Chinese medicine, it is characterized in that it primarily of following weight portion raw material obtain: Radix Scutellariae 20 parts, the Cortex Eucommiae 11 parts, Fructus Lycii 8 parts, Radix Salviae Miltiorrhizae 10 parts, Radix Morindae Officinalis 10 parts, towards Herba Epimedii 6 parts, Semen Cassiae 12 parts, Herba Plantaginis 10 parts, Radix Puerariae 16 parts, Herba Taraxaci 12 parts, the Rhizoma Pinelliae 10 parts, Flos Chrysanthemi Indici 15 parts, Folium Artemisiae Argyi 5 parts, 10 parts, Radix Glycyrrhizae.
2. Chinese medicine as claimed in claim 1, is characterized in that described Chinese medicine composition contains Fructus Lycii 6 parts, Herba Ecliptae 12 parts and the Radix Paeoniae Alba 8 parts.
3. Chinese medicine as claimed in claim 1 or 2, is characterized in that described Chinese medicine composition is mixture, tablet or capsule.
4. prepare the method for Chinese medicine as claimed in claim 1 or 2 for one kind, it is characterized in that it comprises the following steps: get each medical material, add the 5-15 water doubly of medical material gross weight, soak 10-60 minute, decoct 1-4 time, each 1-3 hour, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.05-1.25, this relative density is testing result at 60 c, adding ethanol to alcohol content is 60-90% (v/v), leaves standstill 24 hours, gets supernatant, reclaim ethanol to concentrated, to obtain final product.
5. the purposes of Chinese medicine as claimed in claim 1 or 2 in preparation treatment or prophylaxis of hypertension complication with diabetes retinopathy medicine.
CN201410743295.1A 2014-12-06 2014-12-06 Traditional Chinese medicine for treating hypertension complicated with diabetic fundi disease and preparation method thereof Pending CN104435487A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410743295.1A CN104435487A (en) 2014-12-06 2014-12-06 Traditional Chinese medicine for treating hypertension complicated with diabetic fundi disease and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410743295.1A CN104435487A (en) 2014-12-06 2014-12-06 Traditional Chinese medicine for treating hypertension complicated with diabetic fundi disease and preparation method thereof

Publications (1)

Publication Number Publication Date
CN104435487A true CN104435487A (en) 2015-03-25

Family

ID=52882748

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410743295.1A Pending CN104435487A (en) 2014-12-06 2014-12-06 Traditional Chinese medicine for treating hypertension complicated with diabetic fundi disease and preparation method thereof

Country Status (1)

Country Link
CN (1) CN104435487A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105267632A (en) * 2015-10-13 2016-01-27 青岛辰达生物科技有限公司 Traditional Chinese medicine composition composition treating diabetic macular edema
CN108743753A (en) * 2018-08-13 2018-11-06 红河鑫润生物技术开发有限公司 A kind of Chinese medicine composition, preparation method and the usage
CN109966349A (en) * 2019-05-16 2019-07-05 谭大国 A kind of Chinese medicine composition and preparation method thereof for preventing and treating diabetic retinopathy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101274084A (en) * 2007-12-18 2008-10-01 秦庆吉 Medicament for curing hypertension, hyperlipemia and complication thereof
CN101721563A (en) * 2009-11-09 2010-06-09 徐兆云 Three high rehabilitation tea

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101274084A (en) * 2007-12-18 2008-10-01 秦庆吉 Medicament for curing hypertension, hyperlipemia and complication thereof
CN101721563A (en) * 2009-11-09 2010-06-09 徐兆云 Three high rehabilitation tea

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
张兰: "活血化瘀法辨治糖尿病概况", 《实用中医内科杂志》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105267632A (en) * 2015-10-13 2016-01-27 青岛辰达生物科技有限公司 Traditional Chinese medicine composition composition treating diabetic macular edema
CN108743753A (en) * 2018-08-13 2018-11-06 红河鑫润生物技术开发有限公司 A kind of Chinese medicine composition, preparation method and the usage
CN109966349A (en) * 2019-05-16 2019-07-05 谭大国 A kind of Chinese medicine composition and preparation method thereof for preventing and treating diabetic retinopathy

Similar Documents

Publication Publication Date Title
CN102205107B (en) Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof
CN103845418B (en) A kind of Chinese medicine composition for the treatment of retinal hemorrhage and uses thereof
CN108524673A (en) A kind of Chinese medicine composition and its application
CN103690784B (en) The Chinese medicine composition for the treatment of Complicating with Hypentersion nephropathy and preparation method
CN102861287A (en) Chinese medicinal composition for treating damp-heat invasion blood stasis diabetic foot and preparation method thereof
CN104435487A (en) Traditional Chinese medicine for treating hypertension complicated with diabetic fundi disease and preparation method thereof
CN101780227B (en) Traditional Chinese medicine composition for treating acute stroke and preparation method thereof
CN104083640B (en) Traditional Chinese medicinal composition for treating diabetes mellitus and preparation method thereof
CN102885975A (en) Traditional Chinese medicine composition for treating diabetes mellitus
CN105412410A (en) Traditional Chinese medicine preparation for preventing and treating radiographic contrast nephropathy
CN102846824B (en) Traditional Chinese medicinal composition for treating cold dampness blood stasis blocking channel type diabetic feet, and its preparation method
CN106109564A (en) Pharmaceutical composition for the treatment of cerebral thrombosis and preparation method thereof
CN104491612A (en) Purpose of traditional Chinese medicine composition in preparing medicament for treating diabetic retinopathy
CN105343593A (en) Spica prunellae health oral liquid capable of decreasing blood pressure and blood lipid as well as preparation method of spica prunellae health oral liquid
CN104689079A (en) Traditional Chinese medicine composition for treating diabetic retinopathy and preparation method thereof
CN105267632A (en) Traditional Chinese medicine composition composition treating diabetic macular edema
CN104474255A (en) Traditional Chinese medicine composition for treating diabetic retinopathy and preparation method of traditional Chinese medicine composition
CN109528865A (en) It is a kind of for treating the Chinese materia medica preparation and preparation method thereof of person in middle and old age&#39;s ophthalmology disease
CN103989940A (en) Traditional Chinese medicine composition for treating diabetes mellitus
CN106728835B (en) A kind of Chinese medicine for treating diabetes
KR20070025066A (en) Herbal composition for treatment and prevention of diabetes and diabetic complications
CN103599477B (en) A kind of Chinese medicine composition for treating humid-heat stagnation type chronic prostatitis
CN104324139B (en) A kind of pharmaceutical composition treating xerophthalmia
CN104524359B (en) A kind of Chinese medicine composition, its preparation method and application
CN104083644A (en) Medicinal preparation beneficial for removing calculus

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20150325

RJ01 Rejection of invention patent application after publication